Skip to main content

The context you need, when you need it

When news breaks, you need to understand what actually matters — and what to do about it. At Vox, our mission to help you make sense of the world has never been more vital. But we can’t do it on our own.

We rely on readers like you to fund our journalism. Will you support our work and become a Vox Member today?

Join now

Lime, a scooter startup that barely existed two years ago, is now going to be worth $2 billion

Lime is expected to take in $400 million in a round financed primarily by its existing investors.

A man riding a Lime scooter.
A man riding a Lime scooter.
Fiona Goodall/Getty Images

The two-year-old scooter-sharing company Lime is finalizing a new round of fundraising that values the company at about $2 billion excluding the new cash, according to people familiar with the matter.

Lime is expected to take in $400 million in a round financed primarily by its existing investors, the people said. The money is expected to arrive in an initial tranche of $300 million followed by a second $100 million investment.

Lime in recent days has been circulating documents to some of its smaller shareholders and gauging interest in the new fundraising round. Its larger backers include not just venture capital firms like Andreessen Horowitz but also several strategic investors — and maybe someday, buyers? — like Uber and Google’s parent company Alphabet. Some new investors such as Bain Capital Ventures are expected to participate.

Lime declined to comment. Some of the earlier financing details were reported by the Wall Street Journal and Axios.

So, are electric scooters still the next big thing?

Well, the $2 billion valuation, while impressive given the age of the company, reflects humbler ambitions for Lime, which reportedly was initially pitching investors on a valuation that was almost two times as high as the one it ended up securing in this round. The heat around scooter-sharing companies has cooled considerably in recent months: Lime’s primary competitor, Bird, has similarly scaled back some of its fundraising hopes and is raising money at a flat share price.

The company’s price tag also refects the new stakes for Lime’s management team, which has had to rapidly scale its operations and C-suite over the last year. One big question over the next few months is whether Lime’s leadership, led by CEO Toby Sun, will be able to take the company to the next level, especially given its dollar-for-dollar, scooter-for-scooter war with Bird and its CEO, Travis VanderZanden.

Lime this November brought on a highly regarded chief operating officer, veteran tech player Joe Kraus, from Alphabet’s early-stage investing arm, GV.

This article originally appeared on Recode.net.

More in Technology

Podcasts
Are humanoid robots all hype?Are humanoid robots all hype?
Podcast
Podcasts

AI is making them better — but they’re not going to be doing your chores anytime soon.

By Avishay Artsy and Sean Rameswaram
Future Perfect
The old tech that could help stop the next airborne pandemicThe old tech that could help stop the next airborne pandemic
Future Perfect

Glycol vapors, explained.

By Shayna Korol
Future Perfect
Elon Musk could lose his case against OpenAI — and still get what he wantsElon Musk could lose his case against OpenAI — and still get what he wants
Future Perfect

It’s not about who wins. It’s about the dirty laundry you air along the way.

By Sara Herschander
Life
Why banning kids from AI isn’t the answerWhy banning kids from AI isn’t the answer
Life

What kids really need in the age of artificial intelligence.

By Anna North
Culture
Anthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque messAnthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque mess
Culture

“Your AI monster ate all our work. Now you’re trying to pay us off with this piece of garbage that doesn’t work.”

By Constance Grady
Future Perfect
Some deaf children are hearing again because of a new gene therapySome deaf children are hearing again because of a new gene therapy
Future Perfect

A medical field that almost died is quietly fixing one disease at a time.

By Bryan Walsh